Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections.
Dupont L, Snell LB, Graham C, Seow J, Merrick B, Lechmere T, Hallett SR, Charalampous T, Alcolea-Medina A, Huettner I, Maguire TJA, Acors S, Almeida N, Cox D, Dickenson RE, Galao RP, Jimenez-Guardeño JM, Kouphou N, Lista MJ, Pickering S, Ortega-Prieto AM, Wilson H, Winstone H, Fairhead C, Su J, Nebbia G, Batra R, Neil S, Shankar-Hari M, Edgeworth JD, Malim MH, Doores KJ.
Dupont L, et al.
medRxiv [Preprint]. 2021 Jun 8:2021.06.07.21258351. doi: 10.1101/2021.06.07.21258351.
medRxiv. 2021.
PMID: 34127977
Free PMC article.
Updated.
Preprint.
Here, we used sera from individuals infected in wave 1 in the UK to study the long-term cross-neutralization up to 10 months post onset of symptoms (POS), as well as sera from individuals infected with the B.1.1.7 variant to compare cross-neutralizing activity profiles. .. …
Here, we used sera from individuals infected in wave 1 in the UK to study the long-term cross-neutralization up to 10 months post ons …